ESR1 and breast carcinoma: Currently, immunotherapy (such as immune checkpoint inhibitors) is mainly focused on patients of TNBC so far [23,24,25], since ER+ and Her2+ breast cancers are considered “cold tumors”, which are of low MHC-I expression, poor TIL infiltration, and insensitivity to chemotherapy [19,20,21,22].